BFRA - Biofrontera AG

NasdaqCM - NasdaqCM Delayed price. Currency in USD
13.20
0.00 (0.00%)
At close: 12:17PM EDT
Stock chart is not supported by your current browser
Previous close13.20
Open13.20
Bid12.75 x 800
Ask13.30 x 3000
Day's range13.20 - 13.26
52-week range11.25 - 17.98
Volume5,455
Avg. volume6,768
Market cap301.157M
Beta (3Y monthly)0.37
PE ratio (TTM)N/A
EPS (TTM)-0.85
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est20.83
Trade prices are not sourced from all markets
  • GlobeNewswire7 days ago

    Biofrontera to Present at the 4th Annual Dawson James Small Cap Growth Stock Conference

    Frankfurt Stock Exchange: B8F), an international biopharmaceutical company, today announced that Dr. Hermann Lübbert, Biofrontera’s Chief Executive Officer, is scheduled to present at the 4th Annual Dawson James Small Cap Growth Stock Conference, being held on October 29-30, 2018 at Wyndham Grand Hotel in Jupiter, FL.

  • GlobeNewswire12 days ago

    Biofrontera announces preliminary unaudited sales revenue for the first nine months of 2018 and increases revenue guidance

    Biofrontera AG (NASDAQ ticker symbol: BFRA, ISIN: DE0006046113), an international biopharmaceutical company, today announced preliminary unaudited revenue for the first nine months of fiscal year 2018 and increases its revenue guidance. The preliminary unaudited revenue of Biofrontera group for the period January to September 2018 were between EUR 14.5 and 14.7 million. This represents a revenue growth of approximately 98% compared to the previous year period, with pure product sales increasing by around 131%.

  • GlobeNewswire21 days ago

    Swissmedic approves Ameluz® in combination with daylight photodynamic therapy in Switzerland

    Frankfurt Stock Exchange: B8F), an international biopharmaceutical company, announced today that Swissmedic, the Swiss national approval and supervisory authority for drugs and medical products, has approved the extension of the label of Ameluz® to its use in combination with photodynamic daylight therapy (daylight-PDT). The Swiss approval of Ameluz® with daylight-PDT follows the EU approval by the European Commission in March 2018. Ameluz is marketed in Switzerland by Louis Widmer, which also functions as local marketing authorization holder.

  • GlobeNewswire27 days ago

    Biofrontera starts patient recruitment for U.S. Phase III Trial Evaluating Ameluz® / BF-RhodoLED® for Superficial Basal Cell Carcinoma

    Frankfurt Stock Exchange: B8F), an international biopharmaceutical company, today announced that patient enrollment started for its U.S. phase III trial for Ameluz® for the treatment of superficial basal cell carcinoma (BCC). The study investigates the safety and efficacy of conventional photodynamic therapy (PDT) with Ameluz® in combination with the Company’s BF-RhodoLED® lamp.

  • GlobeNewswire28 days ago

    Biofrontera to Present at the Cantor Fitzgerald Global Healthcare Conference

    Frankfurt Stock Exchange: B8F), an international biopharmaceutical company, today announced that Thomas Schaffer, Biofrontera’s Chief Financial Officer, is scheduled to present at the Cantor Fitzgerald Global Healthcare Conference, being held on October 1-3, 2018 at the InterContinental New York Barclay Hotel. Following the presentation, Biofrontera’s CFO Thomas Schaffer will host a breakout session at 5:45pm ET and will also be available for one-on-one meetings with investors who are registered to attend the event.

  • GlobeNewswirelast month

    Biofrontera to present at the Baader Investment Conference

    Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be participating at the Baader Investment Conference. The conference will take place from September 24-27, 2018 at the Sofitel Munich Bayerpost in Munich, Germany. Prof. Dr. Hermann Lübbert, Biofrontera’s CEO, will provide an overview of the Company’s business during the live presentation and will be available for one-one meetings with investors during the conference.

  • GlobeNewswirelast month

    Biofrontera uses the long summer months to introduce daylight photodynamic therapy (PDT) with Ameluz® in the EU

    Frankfurt Stock Exchange: B8F), an international biopharmaceutical company, today announced an update on preliminary EU sales figures for the sunny months of April to August, following the market launch of Ameluz® in combination with daylight-PDT in April. Germany, our largest market in the EU, achieved a significant sales revenue increase of around 63% in the months April to August, with sales more than doubling in June and July compared to the same period last year. In European markets served by our own sales teams, namely Germany, Spain and the U.K., we saw an increase in sales in the same period of approximately 75% compared to the previous year.